H.C. Wainwright Downgrades Galectin Therapeutics (GALT) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
FBR Capital Downgrades Galectin Therapeutics (GALT) to Market Perform
October 3, 2016 6:23 AM EDTFBR Capital downgraded Galectin Therapeutics (NASDAQ: GALT) from Outperform to Market Perform with a price target of $2.00 (from $12.00).
Analyst Vernon Bernardino commented, "On September 27, Galectin Therapeutics announced that NASH-FX had failed to meet its primary and secondary endpoints. The study was one of two ongoing Phase II clinical... More
Roth Capital Downgrades Galectin Therapeutics (GALT) to Sell
September 28, 2016 8:41 AM EDTRoth Capital downgraded Galectin Therapeutics (NASDAQ: GALT) from Buy to Sell with a price target of $0.75.
For an analyst ratings summary and ratings history on Galectin Therapeutics click here. For more ratings news on Galectin Therapeutics click here.
Shares of Galectin Therapeutics closed at $2.47 yesterday.
... MoreGalectin Therapeutics (GALT) Agrees to Sell 1.5M Convertible Preferred Shares
September 27, 2016 4:18 PM EDTGalectin Therapeutics (NASDAQ: GALT) disclosed that on September 22, 2016 it entered into a Securities Purchase Agreement with 10X Fund, L.P., a Delaware limited partnership (Purchaser). Pursuant to the Purchase Agreement, the Company has agreed to issue and sell to Purchaser, and Purchaser has agreed to purchase from the Company at closings held or to be held on September 22, 2016 and September 29, 2016 (i)... More
Galectin (GALT) Reports Exploratory Phase 2a Pilot Trial of GR-MD-02 in Nash Misses Primary Biomarker Endpoint; Announces $1.5M Private Placement
September 27, 2016 4:14 PM EDTGalectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced topline results from NASH-FX, its Phase 2a clinical trial evaluating the efficacy, safety, and tolerability of GR-MD-02 in 30 nonalcoholic steatohepatitis (NASH) patients with advanced fibrosis. This exploratory, single site, short-treatment (four months of therapy), randomized study did not meet its primary biomarker endpoint as measured by LiverMultiScan (LMS, Perspectum Diagnostics), a magnetic resonance imaging test that evaluates inflammation and fibrosis. The trial also did not meet secondary endpoints that measure liver stiffness as a... More
